On June 20, Mr. Huo and his delegation from Zibo Xinda Pharmaceutical Co., Ltd. came to our institute to discuss work.

Shandong Zibo Xinda Pharmaceutical Co., Ltd. is a "backbone enterprise of the national Torch Plan biomedical industry base" and one of the first batch of "GMP certification" and "ISO14001 international environmental protection certification" dual certification enterprises in China. It was established in 1993 with a registered capital of 84.93 million yuan, of which Shandong Xinhua Pharmaceutical Group accounts for 80% of the shares and Shandong Xinhua Pharmaceutical Co., Ltd. accounts for 20% of the shares. Shandong Xinhua Pharmaceutical Group, the holding parent company, has a total assets of more than 3 billion yuan and is known as the largest production and export base of antipyretic analgesics in China. Xinda pharmaceutical is the core subsidiary of Xinhua Group, which has gathered a large number of high-quality scientific and technological personnel. It has become a famous oral anti infective drug production base and children's drug production base in China, as well as an important middle-aged and elderly drug production base in China. "Xinda Luo" is a famous antibiotic brand for children and adults in China.

Our institute has established a long-term cooperative relationship with Xinda Pharmaceutical Co., Ltd.